Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Ekso Bionics Holdings Equity-to-Asset Related Terms
Ekso Bionics Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Ekso Bionics Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKSO vs POCI, HBIO, NEPH: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ekso Bionics Holdings Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Ekso Bionics Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Ekso Bionics Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ekso Bionics Holdings (EKSO) has a Equity-to-Asset of 0.29 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ekso Bionics Holdings and its competitors. This is 36% below median its historical median of 0.45.
Is Ekso Bionics Holdings' Equity-to-Asset too high?
Ekso Bionics Holdings' current Equity-to-Asset of 0.29 is 36% below median its 10-year median of 0.45. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Ekso Bionics Holdings' value of 0.29 is 54.7% below this industry median. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Ekso Bionics Holdings' Equity-to-Asset compare to POCI and HBIO?
Ekso Bionics Holdings' Equity-to-Asset of 0.29 can be compared against companies in the Medical Devices & Instruments industry. The industry median Equity-to-Asset is 0.64. Ekso Bionics Holdings' value of 0.29 is 54.7% below this benchmark. While the company's 10-year median is 0.45 vs. the industry median of 0.64, Ekso Bionics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ekso Bionics Holdings's current Equity-to-Asset of 0.29 is 54.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ekso Bionics Holdings and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ekso Bionics Holdings's current Equity-to-Asset is 0.29, which is 36% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekso Bionics Holdings stock overvalued right now?
Ekso Bionics Holdings (EKSO) has a current Equity-to-Asset of 0.29. The stock's GF Value™ is $4.40, compared to a current price of $11.65 — trading 164.8% above its estimated fair value. The current Equity-to-Asset is 0.29, which is 36% below median its 10-year median of 0.45 and 54.7% below the Medical Devices & Instruments industry median of 0.64. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current Equity-to-Asset is 0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?
Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued.
The current stock price of $11.65 is trading 164.8% above its estimated GF Value™ of $4.40.
Key valuation signals for EKSO:
Equity-to-Asset: 0.29 (36% below median its 10-year median of 0.45)
GF Value™: $4.40 vs. price of $11.65 (164.8% above fair value)
Industry Position: 54.7% below the Medical Devices & Instruments median
No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
32GF Score
Get the complete analysis for EKSO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKSO has been successfully added to your 
